Previous 10 | Next 10 |
2023-06-06 08:19:00 ET HTG Molecular Diagnostics ( HTGM ) -40% . Ucommune International ( UK ) -16% . EZGO Technologies EZGO -8% on $8.5M direct offering . Timber Pharmaceuticals ( TMBR ) -10% . Celestica CLS -8% on pricing secondary sto...
2023-06-05 13:06:50 ET Gainers: Forza X1 ( FRZA ) +164% . Sono Group ( SEV ) +123% . Chijet Motor Company ( CJET ) +62% . CIRCOR International ( CIR ) +51% . Timber Pharmaceuticals ( TMBR ) +44% . TOP Financial Group ( TOP ...
2023-06-05 12:52:29 ET Shares of micro-cap Timber Pharmaceuticals ( NYSE: TMBR ) soared as much as 83% on Monday after the company was granted a waiver from the U.S. Food and Drug Administration (FDA) to forgo a rodent study for its investigational treatment TMB-001. ...
2023-06-05 10:06:47 ET Gainers: Timber Pharmaceuticals ( TMBR ) +36% . Amedisys ( AMED ) +15% . Rockwell Medical ( RMTI ) +15% . Coeptis Therapeutics ( COEP ) +14% . BiondVax Pharmaceuticals ( BVXV ) +12% . Losers: Bellerophon ...
- Phase 3 ASCEND study of TMB-001 (topical isotretinoin) for the treatment of congenital ichthyosis is 70% enrolled - WARREN, NJ, June 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a cli...
2023-05-15 17:02:56 ET Timber Pharmaceuticals press release ( NYSE: TMBR ): Q1 GAAP EPS of -$1.32. As of March 31, 2023, Timber had approximately $5.2 million in cash and approximately 3.0 million shares of common stock outstanding. For further details see: Timbe...
- Timber has now Enrolled Over 60% of Patients for Pivotal TMB-001 Phase 3 ASCEND Clinical Trial - WARREN, NJ, May 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a clinical-stage bi...
2023-04-03 00:59:33 ET Timber Pharmaceuticals press release ( NYSE: TMBR ): FY GAAP EPS of -$9.19. Revenue of $0.08M (-91.0% Y/Y) misses by $0.72M . At December 31, 2022, Timber had approximately $9.1M in cash, which included $1.3M in gross proceeds raised through ...
- Lead asset TMB-001 is only compound to receive official orphan drug designation from European Commission for two severe subtypes of congenital ichthyosis, ARCI and XLRI - - Timber has enrolled 50% of patients for pivotal TMB-001 Phase 3 ASCEND clinical trial - WARREN, NJ, ...
- Treatment with TMB-001 demonstrated greater proportions of participants achieving primary and key secondary endpoints versus vehicle regardless of the subtype of congenital ichthyosis - BASKING RIDGE, NJ, March 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceutical...
News, Short Squeeze, Breakout and More Instantly...
Timber Pharmaceuticals Inc. Company Name:
TMBR Stock Symbol:
NYSE Market:
WARREN, N.J., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Timber Pharmaceuticals, Inc. ("Timber" or the "Company") (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today announced that...
WARREN, NJ - ( NewMediaWire ) - November 28, 2023 - Timber Pharmaceuticals, Inc. (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, and its affiliated debtors and debtor-...
WARREN, NJ, Nov. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, and its affiliated d...